Sildenafil (Viagra, Pfizer Pharmaceuticals) is an orally active, potent, and selective Phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is the major PDE subtype responsible for cGMP hydrolysis, and it is abundant in the pulmonary vasculature [1]. The therapeutic use of this drug in pulmonary hypertension improves the pulmonary vascular haemodynamics and therefore the exercise capacity of patients [2]. The treatment involves the administration of high doses daily, and until now, little is know about the action of this scheme on testis cells. Recently, the expression of PDE5 was detected on Leydig and myoid cells of pre-pubere and adult rat testis [3]. Then, it is necessary to investigate if compounds that interfere on PDE5 activity could affe...
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vasc...
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) ...
Erectile dysfunction and Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostate Hyperplasi...
O inibidor de fosfodiesterase-5 (PDE5), Sildenafil, é uma nova abordagem de tratamento oral para a h...
Purpose: We identify whether tachyphylaxis and priapism effects of sildenafil are related to regulat...
Sildenafil citrate revolutionized the practice of sexual medicine upon its federal regulatory agency...
Sildenafil citrate, a specific phosphodiesterase-5 (PDE-5) inhibitor drug currently used for the tre...
1. The anococcygeus muscle is part of the erectile machinery in male rodents. Phosphodiesterase (PDE...
1. The anococcygeus muscle is part of the erectile machinery in male rodents. Phosphodiesterase (PDE...
Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile d...
Phosphodiesterase (PDE)-5 degrades guanosine 3',5'cyclic monophosphate (cGMP) and its inhibitor sild...
Introduction: Orally active phosphodiesterase type 5 inhibitors (PDE5i), used in the treatment of er...
Type 5 phosphodiesterase (PDE5) blockade by inhibitors (PDE5i) results in intracellular cyclic guano...
Different adipose tissue (AT) depots are associated with multiple metabolic risks. Phosphodiesterase...
The cGMP-binding cGMP-specific phosphodiesterase (PDE5) degrades cGMP and regulates the intracellula...
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vasc...
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) ...
Erectile dysfunction and Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostate Hyperplasi...
O inibidor de fosfodiesterase-5 (PDE5), Sildenafil, é uma nova abordagem de tratamento oral para a h...
Purpose: We identify whether tachyphylaxis and priapism effects of sildenafil are related to regulat...
Sildenafil citrate revolutionized the practice of sexual medicine upon its federal regulatory agency...
Sildenafil citrate, a specific phosphodiesterase-5 (PDE-5) inhibitor drug currently used for the tre...
1. The anococcygeus muscle is part of the erectile machinery in male rodents. Phosphodiesterase (PDE...
1. The anococcygeus muscle is part of the erectile machinery in male rodents. Phosphodiesterase (PDE...
Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile d...
Phosphodiesterase (PDE)-5 degrades guanosine 3',5'cyclic monophosphate (cGMP) and its inhibitor sild...
Introduction: Orally active phosphodiesterase type 5 inhibitors (PDE5i), used in the treatment of er...
Type 5 phosphodiesterase (PDE5) blockade by inhibitors (PDE5i) results in intracellular cyclic guano...
Different adipose tissue (AT) depots are associated with multiple metabolic risks. Phosphodiesterase...
The cGMP-binding cGMP-specific phosphodiesterase (PDE5) degrades cGMP and regulates the intracellula...
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vasc...
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) ...
Erectile dysfunction and Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostate Hyperplasi...